Related Experiment Video
Updated: Jan 7, 2026
Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
From Polymorphisms to Phenotypes: SMAD3 rs17293632 and LTBP3 rs11545200 in Pediatric Inflammatory Bowel Disease
Jan Brylak1, Mariusz Szczepanik1, Jan K Nowak1
1Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, 60-572 Poznan, Poland.
Insights
Genetic variants in SMAD3 and LTBP3 influence pediatric inflammatory bowel disease (IBD) severity. These findings may help tailor treatments for children with Crohn's disease (CD) and ulcerative colitis (UC).
Area of Science:
- Genetics and Genomics
- Pediatric Gastroenterology
- Immunology
Background:
- Early-onset inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), often exhibits a more severe clinical trajectory.
- Genetic factors, particularly within the transforming growth factor-beta (TGF-β) signaling pathway, are critical in IBD pathogenesis.
- SMAD3 and LTBP3 genes, integral to TGF-β signaling, have been previously linked to IBD through genome-wide association studies.
Purpose of the Study:
- To investigate the clinical relevance of specific polymorphisms in SMAD3 (rs17293632) and LTBP3 (rs11545200) within a pediatric IBD cohort.
- To correlate these genetic variants with clinical disease characteristics, including age at diagnosis, inflammatory markers, growth parameters, and treatment responses.
Main Methods:
- A cohort of 286 pediatric patients (133 with UC, 153 with CD) was recruited from seven Polish pediatric centers.
- Genotyping was performed for the SMAD3 rs17293632 and LTBP3 rs11545200 polymorphisms.
- Clinical data collected included age at diagnosis, C-reactive protein (CRP) levels, albumin levels, weight, height, BMI Z-scores, and therapeutic interventions.
Main Results:
- The minor allele of LTBP3 rs11545200 was significantly associated with earlier diagnosis, poorer nutritional status during flares, and increased infliximab use, especially in UC patients.
- In CD patients, the SMAD3 rs17293632 major homozygous genotype correlated with higher systemic corticosteroid usage, indicating a potentially more severe or refractory disease phenotype.
- These genetic variations within the TGF-β pathway are linked to distinct clinical presentations in pediatric IBD.
Conclusions:
- Polymorphisms in LTBP3 and SMAD3 are associated with specific clinical features in pediatric IBD patients.
- These genetic markers may serve as predictive biomarkers for disease severity and guide personalized treatment strategies in children with IBD.
- Further research into TGF-β pathway genetics can enhance tailored therapeutic approaches for pediatric IBD.
Abstract:
Background/Objectives: Early-onset inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), frequently presents with a more severe clinical course. Genetic susceptibility, particularly involving the TGF-β signaling pathway, plays a key role in IBD pathogenesis. SMAD3 and LTBP3 encode crucial components of this pathway and have been implicated in IBD in previous genome-wide association studies. Methods: This study aimed to assess the clinical significance of the rs17293632 (SMAD3) and rs11545200 (LTBP3) polymorphisms in a pediatric IBD cohort. A total of 286 children (133 with UC and 153 with CD) were recruited from seven pediatric centers in Poland. Clinical data included age at diagnosis, inflammatory markers (CRP, albumin), growth indices (Z-scores for weight, height, and BMI), and treatment regimens. Results: The LTBP3 rs11545200 minor allele was significantly associated with a younger age at diagnosis, poorer nutritional status during disease flares, and a more frequent use of infliximab-particularly in patients with UC. In CD, the SMAD3 rs17293632 major homozygous genotype was associated with increased use of systemic corticosteroids, suggesting a more severe or treatment-resistant disease phenotype. Conclusions: The assessed polymorphisms in LTBP3 and SMAD3, both involved in TGF-β signaling, are associated with clinical characteristics of pediatric IBD. These findings support the potential role of genetic variants as biomarkers for disease severity and treatment tailoring, contributing to the development of personalised therapeutic strategies in children with IBD.
Related Concept Videos
01:33Pleiotropy
01:35Pedigree Analysis
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...